Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

Recruiting

Phase 1

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

Sponsor:

National Cancer Institute (NCI)

Code:

NCT02390752

Conditions

Neurofibroma, Plexiform

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Promyelocytic, Acute

Sarcoma

Eligibility Criteria

Sex: All

Age: 3 - 35

Healthy Volunteers: Not accepted

Interventions

TURALIO(R)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-15. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-05-20.